AU2013229008B2 - Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof - Google Patents

Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof Download PDF

Info

Publication number
AU2013229008B2
AU2013229008B2 AU2013229008A AU2013229008A AU2013229008B2 AU 2013229008 B2 AU2013229008 B2 AU 2013229008B2 AU 2013229008 A AU2013229008 A AU 2013229008A AU 2013229008 A AU2013229008 A AU 2013229008A AU 2013229008 B2 AU2013229008 B2 AU 2013229008B2
Authority
AU
Australia
Prior art keywords
cells
fasl
mar
hours
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013229008A
Other languages
English (en)
Other versions
AU2013229008A1 (en
Inventor
Nadir Askenasy
Shai Yarkoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellect Biotherapeutics Ltd
Original Assignee
Cellect Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellect Biotherapeutics Ltd filed Critical Cellect Biotherapeutics Ltd
Publication of AU2013229008A1 publication Critical patent/AU2013229008A1/en
Assigned to CELLECT BIOTHERAPEUTICS LTD reassignment CELLECT BIOTHERAPEUTICS LTD Amend patent request/document other than specification (104) Assignors: CELLECT BIOTECHNOLOGY LTD
Application granted granted Critical
Publication of AU2013229008B2 publication Critical patent/AU2013229008B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
AU2013229008A 2012-03-06 2013-03-05 Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof Ceased AU2013229008B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607033P 2012-03-06 2012-03-06
US61/607033 2012-03-06
PCT/IL2013/000026 WO2013132477A1 (en) 2012-03-06 2013-03-05 Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

Publications (2)

Publication Number Publication Date
AU2013229008A1 AU2013229008A1 (en) 2014-09-18
AU2013229008B2 true AU2013229008B2 (en) 2018-11-08

Family

ID=49116028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013229008A Ceased AU2013229008B2 (en) 2012-03-06 2013-03-05 Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

Country Status (11)

Country Link
US (2) US9783778B2 (enExample)
EP (2) EP2823040B1 (enExample)
JP (1) JP6429191B2 (enExample)
KR (1) KR101912982B1 (enExample)
CN (2) CN104245924B (enExample)
AU (1) AU2013229008B2 (enExample)
CA (1) CA2866358C (enExample)
DK (1) DK2823040T3 (enExample)
IL (1) IL234459B (enExample)
RU (1) RU2630301C2 (enExample)
WO (1) WO2013132477A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016116732A (ru) * 2013-10-09 2017-11-15 Сэллект Байотерапьютикс Лтд. Активация гемопоэтических клеток-предшественников путем предтрансплантационного воздействия лигандами рецепторов смерти
WO2016193986A2 (en) 2015-06-05 2016-12-08 Cellect Biotherapeutics Ltd. Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
JP2021534747A (ja) * 2018-08-22 2021-12-16 セレクト バイオセラピューティクス リミテッド アポトーシス感受性細胞のモジュレーション
US20220002363A1 (en) * 2020-07-03 2022-01-06 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating pulmonary disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138597A2 (en) * 2006-05-31 2007-12-06 Styx Llc Methods of selecting stem cells and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS61235752A (ja) 1985-04-11 1986-10-21 Asahi Optical Co Ltd 細胞分離材、分離器および分離方法
IT8523298V0 (it) * 1985-10-02 1985-10-02 Pierrel Hospital Spa Catetere venoso centrale.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4979959A (en) 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
US4885234A (en) 1988-09-29 1989-12-05 Eastman Kodak Company Photographic materials containing stable cyan coupler formulations
US5998024A (en) 1995-02-02 1999-12-07 Rainer H. Frey Biocompatible material and method of manufacture and use thereof
EA002819B1 (ru) 1997-05-14 2002-10-31 Авентис Фармасьютикалз Продактс Инк. Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция
US6040182A (en) 1997-11-12 2000-03-21 Becton Dickinson And Company Method and materials for efficiency protein immobilization on tissue culture treated assay plates
GB9724270D0 (en) 1997-11-17 1998-01-14 Babraham The Inst Methods and means for mutagenesis of dna
EP1076635B1 (en) 1998-04-22 2002-03-06 St. Jude Medical AB Biocompatible material for implants
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
US20090130718A1 (en) 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2003002761A1 (en) 2001-06-29 2003-01-09 Novozymes A/S Method of multimerization and site-directed mutagenesis
US20030044389A1 (en) 2001-07-02 2003-03-06 Brown Patrick O. Microarrays for cell phenotyping and manipulation
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
ATE519115T1 (de) * 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US20060009623A1 (en) 2004-07-06 2006-01-12 National University Of Singapore C-terminal attachment of ligands to proteins for immobilization onto a support
US20080241109A1 (en) * 2004-10-01 2008-10-02 Marc Dupuis Method for Ex-Vivo Purging in Autologous Transplantation
US8252587B2 (en) * 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
DE602005008265D1 (de) * 2005-12-23 2008-08-28 Biedermann Motech Gmbh Flexible Stabilisierungsvorrichtung zur dynamischen Stabilisierung von Knochen oder Wirbeln
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
AU2008229636B2 (en) * 2007-03-16 2014-08-14 Qiagen Sciences Llc A cell-mediated immune response assay and kits therefor
KR100920729B1 (ko) 2007-10-01 2009-10-07 한국생명공학연구원 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
EP2282786B1 (en) 2008-06-13 2015-10-28 Smith & Nephew, Inc. Fixation devices for tissue repair
WO2010051032A1 (en) * 2008-10-31 2010-05-06 Synthes Usa, Llc Method and device for activating stem cells
GB0823553D0 (en) 2008-12-24 2009-01-28 Immunosolv Ltd Cell separation technique
JP5327457B2 (ja) * 2009-03-27 2013-10-30 セイコーエプソン株式会社 がん細胞分離装置およびその製造方法
JP2010227313A (ja) * 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞除去システムおよびがん細胞除去装置
EP2595637B1 (en) * 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138597A2 (en) * 2006-05-31 2007-12-06 Styx Llc Methods of selecting stem cells and uses thereof

Also Published As

Publication number Publication date
CN109116033A (zh) 2019-01-01
JP2015510758A (ja) 2015-04-13
CN104245924B (zh) 2020-05-01
JP6429191B2 (ja) 2018-11-28
CA2866358C (en) 2020-06-23
RU2630301C2 (ru) 2017-09-06
EP3486315A1 (en) 2019-05-22
EP2823040B1 (en) 2018-08-01
KR20150011796A (ko) 2015-02-02
WO2013132477A1 (en) 2013-09-12
US20150044182A1 (en) 2015-02-12
US20180208888A1 (en) 2018-07-26
CN104245924A (zh) 2014-12-24
KR101912982B1 (ko) 2018-10-29
RU2014138001A (ru) 2016-04-20
AU2013229008A1 (en) 2014-09-18
CA2866358A1 (en) 2013-09-12
US9783778B2 (en) 2017-10-10
EP2823040A1 (en) 2015-01-14
EP2823040A4 (en) 2016-01-06
DK2823040T3 (en) 2018-11-19
IL234459B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
KR101518409B1 (ko) 단핵세포 증량 방법
Boieri et al. The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: a historical overview
Neagu¹ The immune system-a hidden treasure for biomarker discovery in cutaneous melanoma
CN104774261A (zh) Foxm1肽和包含foxm1肽的药剂
US20180208888A1 (en) Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
WO2007082177A2 (en) Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity
EP3303563B1 (en) Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
Zorina New Insights on the Role of the Mesenchymal–Hematopoietic Stem Cell Axis in Autologous and Allogeneic Hematopoiesis
Morecki et al. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators
CN113056555A (zh) 凋亡易感细胞的调节
CN101031642B (zh) 自体移植中离体净化的方法
Shrestha Transient display of chimeric proteins on biological surfaces as an effective strategy for modulations of innate and adaptive immune responses.
Jones The immunobiology of graft-versus-host disease across a minor histocompatibility antigen barrier
Zhou et al. Endogenous C3 expression affects the potency of macrophages as stimulators of T cell alloreactivity
Ushigome et al. GITR activation in donor specific transfusion accelerates allograft rejection
STEM Poster Presentations-Session I
Stepkowski et al. STAT5A/B control survival of t cells by regulating the function of pro-and anti-apoptotic genes during allograft rejection
Wyburn et al. MACROPHAGE-DERIVED INTERLEUKIN-18 IN ACUTE RAT RENAL ALLOGRAFT REJECTION.
Costa et al. ADOPTIVE TRANSFER OF ANTI-CD45RB TREATED LYMPHOCYTES PREVENTS DIABETES MELLITUS ONSET IN NOD MICE
Singer et al. Inhibition of T Cell Activation Through Interruption of Adaptor Protein Associations
Azimzadeh et al. MODULATION OF IMMUNE RESPONSES TO HEART ALLOGRAFTS BY DONOR BONE MARROW INFUSION IN MONKEYS TREATED WITH CD154 COSTIMULATION BLOCKADE
Bentlejwesky et al. KINETICS OF T CELL MEMORY RECOVERY IN LUNG TRANSPLANT RECIPIENTS TREATED WITH T CELL DEPLETION THERAPIES
Deng et al. THE ROLE OF B CELLS IN ANTI-CD45RB INDUCED TRANSPLANTATION TOLERANCE.
Tokita et al. LIVER SINUSOIDAL ENDOTHELIAL CELLS ENDOCYTOSED ALLOGENEIC CELLS TOLERIZE T CELL RECOGNIZING ALLO-ANTIGENS THROUGH INDIRECT RECOGNITION BY FAS-FAS LIGAND PATHWAY.
Lee et al. LIVER STELLATE CELLS SUPPRESS DENDRITIC CELLS THROUGH IL-10

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CELLECT BIOTHERAPEUTICS LTD

Free format text: FORMER NAME(S): CELLECT BIOTECHNOLOGY LTD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired